On Tuesday, BofA Securities revised its stance on BioXcel Therapeutics (NASDAQ:BTAI) stock, downgrading it from Neutral to Underperform. The firm also significantly reduced the price target to $0.25, a steep decline from the previous target of $7.00.
With a current market capitalization of just $28.45 million and total debt of nearly $105 million, this reassessment by BofA Securities reflects a cautious outlook for the biopharmaceutical company over the next year. According to InvestingPro data, the company is currently trading above its calculated Fair Value.
BioXcel Therapeutics is at a pivotal juncture, relying heavily on the outcomes of its phase 3 SERENITY study, which focuses on treating agitation associated with bipolar disorder and schizophrenia.
The study, which began enrolling participants in September 2024, is expected to rapidly progress towards topline data anticipated in the second half of 2025. Moreover, BioXcel’s second phase 3 study, TRANQUILITY, aimed at addressing Alzheimer’s-associated agitation, is on the horizon pending feedback from the FDA.
Despite the potential for positive data from these studies to bolster the company’s stock, BofA Securities expresses concern over several factors. The analyst cited issues with previous trials, unstable commercial performance of BioXcel’s drug IGALMI, and a dwindling cash reserve as reasons for caution.
InvestingPro analysis reveals the company is quickly burning through cash, with a concerning current ratio of 1.87. The recent capital raise of $7 million is projected to extend the company’s financial runway by merely five to six months, according to BofA Securities’ estimates. Get access to 11 more key ProTips and comprehensive financial analysis with an InvestingPro subscription.
The downgrade and new price objective underscore the heightened risk profile for BioXcel Therapeutics as it navigates critical clinical trials and strives to improve its financial standing. Despite the challenges, the stock has shown a significant return of over 53% in the past week, though it remains down nearly 80% over the past year.
BofA Securities’ adjustment of the stock’s rating and target price reflects these concerns and the uncertainty surrounding the company’s near-term prospects. For deeper insights into BTAI’s financial health and future potential, access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, BioXcel Therapeutics has seen significant financial and strategic developments. The company’s Q3 2024 net revenue was $214,000, a decrease from the previous year, but the nine-month revenue increased to $1.9 million, and the net loss was significantly reduced to $13.7 million.
Canaccord Genuity adjusted its outlook on BioXcel Therapeutics shares, reducing the price target to $5 while maintaining a Buy rating. Mizuho (NYSE:) Securities, however, maintained its Neutral rating, citing low sales of the drug Igalmi and higher operating expenses.
BioXcel Therapeutics has made significant modifications to its credit agreement, including issuing new warrants to lenders and adjusting its capital raising requirements. The company now needs to secure a series of funds by specific dates tied to the SERENITY At-Home Phase 3 trial results. Moreover, the company has agreed to a fixed interest rate of 13% per annum on its loans and has committed to appointing a new independent board director to explore strategic options.
BioXcel is actively advancing its clinical trials, including the initiation of two pivotal Phase 3 trials for drug candidate BXCL501. The company has also launched the Phase 3 SERENITY At-Home study for Igalmi, with top-line data expected by the third quarter of 2025.
These are among the recent developments shaping BioXcel’s trajectory as the company explores strategic financing options and discusses potential partnerships to address its immediate liquidity challenges and support its ongoing clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
